Cargando…
The pipeline of new molecules and regimens against drug-resistant tuberculosis
The clinical development and regulatory approval of bedaquiline, delamanid and pretomanid over the last decade brought about significant progress in the management of drug-resistant tuberculosis, providing all-oral regimens with favorable safety profiles. The Nix-TB and ZeNix trials of a bedaquiline...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593651/ https://www.ncbi.nlm.nih.gov/pubmed/34816020 http://dx.doi.org/10.1016/j.jctube.2021.100285 |